SB 180-FN - AS INTRODUCED

2023 SESSION

23-0766 09/10

SENATE BILL 180-FN

AN ACT relative to product labeling and information guide requirements for cannabis

products.

SPONSORS: Sen. Avard, Dist 12; Sen. Carson, Dist 14; Sen. Gannon, Dist 23

COMMITTEE: Judiciary

ANALYSIS

This bill revises the warning labels that are placed on marijuana products sold at alternative treatment centers; and requires that a product information guide be distributed by the alternative treatment centers with their marijuana products.

Explanation: Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

STATE OF NEW HAMPSHIRE

In the Year of Our Lord Two Thousand Twenty Three

AN ACT relative to product labeling and information guide requirements for cannabis products.

Be it Enacted by the Senate and House of Representatives in General Court convened:

1 New Sections; Product Label and Information Guide Requirements. Amend RSA 126-X by inserting after section 126-X:12 the following new sections:

126-X:13 Product Label and Information Guide.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

I. No later than 90 days after the effective date of this section, the commissioner of the department of health and human services shall adopt rules which change the warning label on marijuana products sold via alternative treatment centers to read as follows:

"This product has not been analyzed or approved by the FDA. It is not certified to be free of contaminants. There is information on the side effects of using this product, and there are associated health risks. Do not drive or operate heavy machinery when under the influence of this product. KEEP THIS PRODUCT AWAY FROM CHILDREN."

- II. Not later than 90 days after the effective date of this section, the commissioner of the department of health and human services shall develop a product information guide which details issues that are specific to marijuana use. This product information guide shall be scientifically accurate and based upon the most recent Centers for Disease Control and Prevention and U.S. Department of Health and Human Services data, shall not be promotional in tone or content, and shall include a date of publication. A copy of this product information guide shall be provided to alternative treatment centers for duplication and distribution. This product information guide shall identify the following:
 - (a) Activities that individuals should avoid when using marijuana;
- (b) A statement about risks to mothers and fetuses from use during pregnancy, including impacts on fetal development;
 - (c) A statement about risks of cannabis use to nursing infants;
 - (d) A statement about pediatric risks associated with cannabis exposure and ingestion;
 - (e) A statement about risks associated with cannabis use in adolescents;
 - (f) A statement of the possible physical and psychiatric side effects of adult cannabis use;
 - (g) A statement of the adverse reactions that can be caused by cannabis use;
- (h) A statement that details marijuana use disorder and the risk of developing this disorder while consuming cannabis product.
- III. This product information guide shall be reviewed annually by the department and a report of this review shall be provided to the Cannabis Medical Oversight Board within 30 days after

SB 180-FN - AS INTRODUCED - Page 2 -

- the completion of the review. This review shall also be publicly available on the department's website. If there are any recommended changes to this information guide, a new document shall be provided to alternative treatment centers no later that 60 days after the annual review is completed.

 126-X:14 Product Information Guide Distribution. All cannabis dispensed by an alternative treatment center shall include a product information guide attached to the package. This product information guide shall be developed by the department of health and human services and a copy will be provided to the alternative treatment services for duplication and distribution.
- 2 Effective Date. This act shall take effect 60 days after its passage.

SB 180-FN- FISCAL NOTE AS INTRODUCED

AN ACT

relative to product labeling and information guide requirements for cannabis products.

FISCAL IMPACT:

Due to time constraints, the Office of Legislative Budget Assistant is unable to provide a fiscal note for this bill, <u>as introduced</u>, at this time. When completed, the fiscal note will be forwarded to the Senate Clerk's Office.

AGENCIES CONTACTED:

Department of Health and Human Services